作者
Abhishek Maiti, Courtney D DiNardo, Jorge E Cortes, Gautam Borthakur, Naveen Pemmaraju, Christopher B Benton, Tapan M Kadia, Koichi Takahashi, Kiran Naqvi, Farhad Ravandi, Yesid Alvarado, Nicholas J Short, Naval G Daver, Koji Sasaki, Maro N Ohanian, Guillermo Garcia-Manero, Philip A Thompson, Steven M Kornblau, Lucia Masarova, Nitin Jain, Elias J Jabbour, Michael Andreeff, Rita Maduike, Julio A Guerrero, Qi Zhang, Antonio Cavazos, Helen Ma, Caitlin R Rausch, Carol A Bivins, Kenneth Vaughan, Sherry A Pierce, Jing Ning, Wei Qiao, John S Welch, Hagop M Kantarjian, Marina Y Konopleva
发表日期
2018/11/29
期刊
Blood
卷号
132
页码范围
286
出版商
Content Repository Only!
简介
Background: Patients (pt) with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are elderly, or have secondary AML (sAML), or relapsed/refractory (R/R) disease have poor outcomes. Venetoclax (VEN), an oral BCL2 inhibitor, has shown activity in R/R AML as single-agent and in combination with hypomethylating agents (HMA) in newly diagnosed unfit AML. We designed a phase II trial to evaluate the safety and efficacy of VEN with 10-days (D) of decitabine (DEC) in AML and high risk MDS.
Methods: Eligible AML pts included those who had failed prior therapy, or were newly diagnosed (ND) elderly pts (>60 years), or had sAML. ECOG score ≤3, WBC count ≤10 x109/L, and adequate organ function were required. VEN was given on day 1-28 in cycle (cy) 1 and D1-21 in cy 2 onwards; and was interrupted on C1D21 if the 21D bone marrow showed clearance of blasts, until count recovery …
学术搜索中的文章
A Maiti, CD DiNardo, JE Cortes, G Borthakur… - Blood, 2018